Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Shares of early-stage biotech stocks, including Biohaven ( BHVN -6.50%), Recursion Pharmaceuticals ( RXRX -7.37%), and CRISPR ...

As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, ...

Learn more about whether Corcept Therapeutics Incorporated or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...

Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting ...